Indivior director acquires 42,009 shares in merger
The merger also converted equity awards, including restricted stock units scheduled to settle on February 18, 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Indivior Pharmaceuticals, Inc. (INDV) reported that director Georges Gemayel acquired 42,009 shares of Supernus, Inc. common stock in the merger effective November 2, 2026. Each outstanding share of Supernus Pharmaceuticals common stock converted into the right to receive 1.5401 shares of Indivior common stock, and Indivior changed its name to Supernus, Inc. in connection with the merger. Gemayel received no cash consideration except cash in lieu of a fractional share.
His equity awards were also converted. The reported awards include 4,603 restricted stock units, which are settled in common stock upon vesting on February 18, 2027. Converted option awards retained substantially the same terms, including vesting; their per-share exercise prices were adjusted using the exchange ratio and rounded up to the nearest whole cent.
Insider Trade Summary
Other: 165,827 shares
Other
12 txns
Insider
GEMAYEL GEORGES
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Restricted Stock Units F2, F3 | 4,603 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 9,296 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 13,264 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 19,138 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 14,330 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 11,342 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 10,545 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 9,691 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 12,708 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 11,236 | $0.00 | $0.00 |
| Other | Director Stock Option (right to buy) F2 | 7,665 | $0.00 | $0.00 |
| Other | Common Stock F1 | 42,009 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 4,603 contracts (Direct);
Director Stock Option (right to buy) — 119,215 contracts (Direct);
Common Stock — 42,009 shares (Direct)
Footnotes (3)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
- F2. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units.
- F3. These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027.
Key Figures
Common shares acquired: 42,009 shares
Restricted stock units: 4,603 shares
Converted option award: 9,296 shares at a $25.07 exercise price per share
+4 more
7 metrics
Common shares acquired
42,009 shares
Merger effective November 2, 2026
Restricted stock units
4,603 shares
Settle in common stock upon vesting on February 18, 2027
Converted option award
9,296 shares at a $25.07 exercise price per share
Reported in the merger-related award conversion
Converted option award
13,264 shares at a $25.59 exercise price per share
Reported in the merger-related award conversion
Converted option award
19,138 shares at a $23.87 exercise price per share
Reported in the merger-related award conversion
Converted option award
7,665 shares at a $32.60 exercise price per share
Reported in the merger-related award conversion
Merger exchange ratio
1.5401 shares
Indivior common shares for each outstanding Supernus Pharmaceuticals common share
Key Terms
exchange ratio, restricted stock units, exercise price
3 terms
exchange ratio financial
"multiplied by the 1.5401 exchange ratio"
The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.
restricted stock units financial
"settled in common stock upon vesting"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise price financial
"per-share exercise price divided by the exchange ratio"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happened to Georges Gemayel’s equity awards in the INDV merger?
His outstanding equity awards were assumed and automatically converted into corresponding Supernus, Inc. awards. The reported restricted stock units cover 4,603 shares and are settled in common stock upon vesting on February 18, 2027. Converted awards retained substantially the same terms, including vesting, with option exercise prices adjusted using the exchange ratio and rounded up to the nearest whole cent.
AI-generated analysis. How Rhea-AI works. Not financial advice.
